Parkcellbio, a pioneer in immuno-oncology treatments, has announced that it has submitted an application to the [Relevant Regulatory Authority] to expand the indication of its novel immunotherapy drug, Boxrukin-15, to include canine lymphoma.

Boxrukin-15, the world’s first immunotherapy drug approved for canine mammary tumors, has shown promising results in clinical trials. The latest application seeks to expand the drug’s use to treat lymphoma, one of the most common types of canine cancer.

In clinical trials comparing Boxrukin-15 to standard treatments, the drug demonstrated a significant reduction in tumor size, with a 77.8% reduction rate in the treatment group compared to 57.9% in the control group. These findings have generated significant interest in the veterinary oncology community.

"We are excited about the potential of Boxrukin-15 to transform the treatment of canine cancer," said [CEO's Name], CEO of Parkcellbio. "With the expanded indication, we believe that Boxrukin-15 can become a standard of care for dogs with lymphoma and other types of cancer."

To meet the anticipated increase in demand, Parkcellbio has also submitted an application to modify the manufacturing process and extend the shelf life of the drug.

The company is confident that the approval of this expanded indication will open new markets for Boxrukin-15 and solidify Parkcellbio's position as a global leader in veterinary oncology.